I am studyingcombination therapies in TNBC and I want to know weather MDA-MB-453 belongs to TNBC sub type.
I have found conflicting views on this subject. My own FACS analyses of this cell line (certified) have consistently indicated it has very high surface expression of HER-2. I have also found literature that agrees that MDA-MB-453 expresses HER-2:
- Holliday & Spears, 2011, Choosing the right cell line for breast cancer
research, Breast Cancer Research, 13:215 (available online: http://breast-cancer-research.com/content/pdf/bcr2889.pdf)
- Shim et al., 2012, Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir, Journal of the National Cancer Institute, October 2012 (available online: http://jnci.oxfordjournals.org/content/early/2012/10/05/jnci.djs396.full)
- Park et al xxxx, Targeting the c-erbB-2 proto-oncogene with monoclonal antibodies. In: Lemone and Epenetos, xxxx, Mutant Oncogenes: Targets for Therapy, Chapman & Hall Medical, p.3-9
Given the conflicting data available, I am choosing the accept those that reflect my own research and assume the cell line is HER-2 positive (I have not personally assessed ER or AR expression).
Dear Anil,
Yes MDA-MB-453 is a TNBC cell line model. Try using the following link which gives information about "Cell Line Models for Triple Negative Breast Cancer Subtypes"
Same thing, try to prove it by WB or IHC or IF, don't rely on what others say.
Hello,
Yes it is , Follow the link belw and select the 'cancer cell line mutation data' you can see a panel of triple negative brast cancer, MDA MB is one among them, or use can use this article.
http://www.atcc.org/products/all/HTB-131.aspx#11F1A8C17A7A4FB8A36940C154A9B585
or
http://www.jci.org/articles/view/45014
You would like to see this article : http://www.ncbi.nlm.nih.gov/pubmed/22579283
I think this would help your research.
No, it is not triple negative breast cancer. Pls see Neve et al, 2006 paper.
Atcc claims as TNBC but our own experienced working with these cells showed these cells are not triple negative.These cells are Her2 positive on our hand. http://www.ncbi.nlm.nih.gov/pubmed/17157791
I have found conflicting views on this subject. My own FACS analyses of this cell line (certified) have consistently indicated it has very high surface expression of HER-2. I have also found literature that agrees that MDA-MB-453 expresses HER-2:
- Holliday & Spears, 2011, Choosing the right cell line for breast cancer
research, Breast Cancer Research, 13:215 (available online: http://breast-cancer-research.com/content/pdf/bcr2889.pdf)
- Shim et al., 2012, Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir, Journal of the National Cancer Institute, October 2012 (available online: http://jnci.oxfordjournals.org/content/early/2012/10/05/jnci.djs396.full)
- Park et al xxxx, Targeting the c-erbB-2 proto-oncogene with monoclonal antibodies. In: Lemone and Epenetos, xxxx, Mutant Oncogenes: Targets for Therapy, Chapman & Hall Medical, p.3-9
Given the conflicting data available, I am choosing the accept those that reflect my own research and assume the cell line is HER-2 positive (I have not personally assessed ER or AR expression).
MB-453 cells were called HER2 IHC 2+ without amplification by FISH, when processed alongside clinical samples at our institution. By the standard definition of her2 status as used in adjuvant trastuzumab trials, mb-453 would be considered her2 positive.
That said, most her2+ cell lines have dramatically higher her2 expression, and much greater sensitivity to her2 inhibition, than MB-453.
the main features of mb-453 are expression of luminal and ER related genes, without expression of ER, and with high AR expression.
Western blot analysis of MDAMB453 whole cell lysate indicates detectable but very weak expression of HER2 (data not published). Antibody did not cross-react with other HER family members.
I concur with Heather, same results in Western Blot. Very weak band, especially when compared with SKBR3 and BT474. However, expression levels in flow cytometry were much more comparable between these three cell lines (HER2 negative cell lines were used as negative control for comparison). There seems to be some discord in different methods of detection. Belsches-Jablonski et al (2001) explores this a little.
Yes and no. As others have said: they have detectable levels of HER2, making them HER2 positive. If you do a Western blot with them and, say, MDA-MB-231, the 453 will look to be blazing.
But the HER2 is not amplified, the way it is in other HER2+ breast cancer. If you do the Western blot vs. some other HER2+ breast cancer, the 453 will look very low.
So in some situations, it will behave like a HER2+ cell. In others, it will behave more like a triple negative cell. In terms of your particular study, I'd either just skip this particular cell line, or consider it to be a highly-irregular TNBC, and consider the results accordingly.
I also found the high expression level of her2+ in MDAMB453 at RNA level and protien level
MDA MB453 cell line is not true TNBC cell line, as we have found Her2 expression by IHC and double confirmed by FISH in our lab, but inspite of this it is AR+ breast cancer cell line (confirmed by IHC).
- Badges
- Science topic